Multiple primary malignant tumors in patients with Hodgkin’s lymphoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The presence of >2 malignant neoplasms of different genesis in a patient is considered as a multiple primary malignant tumor. Hodgkin’s lymphoma (HL) is recognized as a potentially treatable disease. The increase in the life expectancy of patients necessitates an examination of 2 (metachronous) malignant tumors in these patients. The incidence of metachronous malignant tumors in patients with HL is higher than that in the population, which should be taken into account during a follow-up.

Full Text

Restricted Access

About the authors

S. Shakhtatina

A.F. Tsyb Medical Radiology Research Center, Branch National Medical Radiology Research Center, Ministry of Health of Russia

Email: shakhtarina@mrrc.obninsk.ru

A. Danilenko

A.F. Tsyb Medical Radiology Research Center, Branch National Medical Radiology Research Center, Ministry of Health of Russia

N. Falaleeva

A.F. Tsyb Medical Radiology Research Center, Branch National Medical Radiology Research Center, Ministry of Health of Russia

S. Ivanov

A.F. Tsyb Medical Radiology Research Center, Branch National Medical Radiology Research Center, Ministry of Health of Russia

A. Kaprin

National Medical Radiology Research Center

References

  1. Злокачественные новообразования в России в 2017 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой / М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018; 250 с.
  2. Давыдов М.И., Аксель Е.М. Статистика злокачественных заболеваний в России и странах СНГ в 2008 г. // Вестник РОНЦ им. Блохина РАМН. - 2010; 21 (2, прил. 1): 52-9
  3. Vanderbroucke J. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio // Am. J. Epidemiol. - 1982; 115: 303-4.
  4. Даниленко А.А., Шахтарина С.В. Лимфома Ходжкина и вторые злокачественные опухоли // Вопр. онкол. - 2009; 55 (6): 692-702
  5. Shakhtarina, S., Danilenko A., Pavlov V. Second cancer risks in patients with supradiaphragmatic Hodgkin lymphoma // Haematologica. - 2016; 101 (Suppl. 5): 71.
  6. Kumar V., Mohit G., Chandra Ad. et al. Trends in the risks of secondary cancers in patients with Hodgkin Lymphoma // Clinical Lymphoma, Myeloma & Leukemia. - 2018; 18 (9): 576-89.
  7. Von Tresckow B., Kreissl S., Goergen H. et al. Intensive treatment strategies in advanced-stage Hodgkin's lumphoma (HD 9 and HD 12): analisis of long-term survival in two randomized trials // Lancet Haematol. - 2018; 10: e462-e473. doi: 10.1016/S2352-3026(18)30140-6.
  8. Wolden S., Hancock S., Carlson R. et al. Management of breast cancer after Hodgkin’s disease // J. Clin. Oncol. - 2000; 18: 765-72.
  9. Ibrahim E., Abouelkhair K., Kazkaz G. et al.Risk of second breast cancer in female Hodgkin's Lymphoma survivors: a meta-analysis // BMC Cancer. - 2012; 12: 197. http://doi.org/10.1186/1471-2407-12-197.
  10. Koh E., Trun T., Heydarian M. A comparison of mantle versus involved-field radiotherapy for Hodgkin's Lymphoma: reduction an normal tissue dose and second cancer risk // Radiation Oncology. - 2007; 2: 13. http://doi.org/10.1186/1748-717X-2-13.
  11. Journi N., Mansouri I., Allodji R. et. al. Volume effects of radiotherapy on the risk of secondary primary cancers: A systematic review of clinical and epidemiological studies // Radiother. Oncol. - 2018; pii: S0167-8140(18)33500-X. doi: 10.1016/j.radonc.2018.09.017.
  12. Travis L., Gospodarowicz M., Curtis R. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease // J. Nat. Cancer Inst. -2002; 94 (3): 182-92.
  13. Шахтарина С.В., Даниленко А.А., Павлов В.В. и др. Влияние противоопухолевой лекарственной и лучевой терапии на состояние щитовидной железы у больных лимфомой Ходжкина в отдаленные сроки наблюдения // Клин. онкогематол. - 2014; 7 (4): 533-9
  14. Каприн А.Д., Галкин В.Н., Жаворонков Л.П. и др. Синтез фундаментальных и прикладных исследований - основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику // Радиация и риск. - 2017; 26 (2): 26-40

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies